All news

A fund manager and its managing member report a 9.99% stake in Citius Oncology (CTOR).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Armistice Capital, LLC and its managing member, Steven Boyd, have reported a 9.99% beneficial ownership stake in Citius Oncology, Inc. (CTOR), totaling 9,394,202 common shares as of September 30, 2026. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as its investment manager, exercising shared voting and dispositive power.

Read original source

CTOR company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.